Drug Discovery

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery #Personalised medicine #Webinar

Webinar: Innovative AI software solutions driving biomarker research

Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More

Webinar date:
Supported by Danaher
#News

#AI #Drug discovery #Financing

DaltonTx set to build AI-enabled drug discovery platforms

UK-based technology company DaltonTx has announced the completion of a £4 million ($5.4 million) financing round to build adaptive AI-enabled drug discovery platforms.  The company, which exited from stealth, is planning on building platforms giving research teams instant access to AI-enabled drug discovery, bypassing their need for… Read More

#News

#Cell Science #Drug discovery

Ebook: Unlocking the power of regenerative medicine

The term “regenerative medicine” is used to refer to methods to replace or regenerate human cells, tissues or organs to restore or establish normal function. This eBook, sponsored by ThinkCyte, examines the latest advances in the sector and the market potential for regenerative medicine. Download this exclusive eBook to… Read More

#DDW eBooks

Human heart
#Cardiovascular disease #Clinical trials #Drug development #Drug discovery

Can human mini-Hearts advance cardiovascular drug development?

By Ronald A Li, PhD, CEO and Co-Founder, Medera, and Kevin D Costa, PhD, Co-Founder, Novoheart. Recent NIH policy prioritising the use of New Approach Methodologies (NAMs) as alternatives to laboratory animals in all new funding opportunities marks a seismic shift in how biomedical research will be conducted. For… Read More

#Exclusive Content

#Cancer research #Drug discovery

PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery – custom webinar with Revvity Sept 2025

In this free-to-attend, 25-minute, bite-sized webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson will be joined during the Q&A… Read More

#Webinars

#Drug discovery #Multi-omics #Omics #Whitepaper

Accelerating pharma innovation with 5D multiomics – download now

Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. A new Whitepaper from Element Biosciences discusses the AVITI24 5D multiomics… Read More

#News

#Drug discovery #Multi-omics #Omics #Whitepaper

Accelerating pharma innovation and drug discovery with 5D multiomics

Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. AVITI24™ 5D multiomics platform offers a new path by capturing RNA,… Read More

#Resources

Artificial intelligence
#AI #Data #Drug discovery #Merck

Merck and Siemens extend partnership for AI projects 

US pharmaceutical giant Merck and technology company Siemens have signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate AI and data-driven drug discovery and development.  The MoU focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to… Read More

#Business & Investment #News

The Francis Crick Institute
#DDW Turning Science into Business Symposium #Drug discovery #Events #The Francis Crick Institute

Nikhil Gupta, CR Horizons, confirmed to speak at DDW Symposium

The DDW Turning Science into Business Symposium will take place at the Francis Crick Institute in London on Tuesday 4 November. Nikhil Gupta DDW is delighted to welcome Nikhil Gupta is Principal Scientist at the Cancer Research Horizons-AstraZeneca Functional Genomics Centre to the expert speaker… Read More

#News

#Drug discovery #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lys Therapeutics awarded $5m to advance neuro pipeline  

French biotech Lys Therapeutics has received a grant award of $5 million (£3.6 million) from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to accelerate the clinical development of its first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders.  The funding… Read More

#News

#Drug discovery #Drug safety #Regulatory

How smaller pharma teams are rethinking safety surveillance 

As global regulatory expectations rise around proactive real-world safety monitoring, smaller marketing authorisation holders risk being caught off-guard with their reliance on rudimentary signal detection practices. Current processes may not support the structured, statistics-based approach favoured by larger companies and expected by health authorities. But there are other… Read More

#Exclusive Content

#Clinical trial #Drug discovery #Gene therapy #Neuroscience #Parkinson's

AskBio begins second phase of gene therapy trial for Parkinson’s  

The first European patients have been randomised in a Phase II gene therapy clinical trial for Parkinson’s disease (PD), AskBio has announced.   The REGENERATE-PD clinical trial is evaluating the safety and efficacy of AskBio’s investigational gene therapy AB-1005 and will enrol approximately 87 patients across clinical trial… Read More

#Editor's Choice #News

#Drug design #Drug discovery #Drug targets #Webinar

Register now: Driving breakthroughs with structure-guided drug design

In this webinar hosted by DDW, Curia shares its findings that protein X-ray crystallography is essential to accelerate the design process by providing a level of structural detail unmatched by computational methods. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding… Read More

#News

Vaccine
#AI #Antibody drug conjugate (ADC) #Biopharma #Drug discovery #Vaccines

DDW Fall issue out now

The DDW Fall issue is out now and examines why there is a need for a universal pneumococcal vaccine, why China might be the next global biopharma powerhouse and looks at developments in microbiome research and the therapeutic sectors it is driving. It also features an exclusive guide exploring… Read More

#News

#Drug discovery #Life sciences #Lithuania

Agreement opens new pathways for Lithuanian life science scale-ups 

Innovation Agency Lithuania and AstraZeneca BioVentureHub (BVH) have signed a Memorandum of Understanding (MoU) at the Life Sciences Baltics 2025 event.   The agreement establishes a framework for collaboration aimed at assisting Lithuanian life science companies in engaging with BVH’s open innovation community in Gothenburg.   It… Read More

#Business & Investment #News

Tumour microenvironment
#Cancer #Drug development #Tumour microenvironment (TME) #Whitepaper

Whitepaper: How protein biomarkers can impact cancer outcomes

Download this whitepaper by Standard BioTools to learn about the tumour microenvironment (TME) and the protein biomarkers helping to shape cancer outcomes. The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression,… Read More

#News